Inasmuch as the phase-2 flu data looked good on both safety and efficacy, the lack of external interest in the program is an enigma.
Yes. Perhaps it's a combo of cost and the threat of an ultimate universal flu vaccine or at least a much better flu vaccine (though the former at least appears to be a ways off).
You meant, norovirus, which VXRT refers to as the lead program.
Oops, yes of course. That's what I get for posting when tired. Given lack of buzz in this CC to me, I think I'm just going to keep VXRT on my radar for a while and don't have plans for any imminent position despite what seems like a pretty cheap valuation to me.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.